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will not occur in my lifetime. Clin Chem 2012;58:169–71.ReplyWe appreciate the concerns expressed in the comments of Drs.
Lippi and Cervellin. The large number of assays available for
cardiac troponin (cTn) and the lack of good comparative data can
be confusing to clinicians. Unfortunately, standardization of cTn
assays is not in our opinion apt to occur, because of the different
antibodies, different instruments, and different biochemical ap-
proaches in use (1). Nor is it likely that companies will reject the
years invested in developing assay platforms, assay techniques, and
antibodies to embrace 1 cTn assay. There is a tension between the
healthy competition that is needed for innovation in the market-
place and confusion caused by a diversity of products in a free-
market economy. We would argue that improvements in the
present assays reﬂect in part individual companies willing to invest
in improving their assays. This tension between innovation and
standardization has beneﬁts with regard to stents, nuclear magnetic
resonance, echocardiographic equipment, as well as cTn assays.
Perhaps ﬁnances will make such choices obligatory, but it is notclear that the beneﬁts of such policies will be greater than the
negatives.
There are, however, areas we should focus on. First, more robust
educational efforts for clinicians are needed. We need to harmonize
approaches among laboratories, emergency departments, and cardi-
ology services. Second, confusion has been induced even in our best
peer-reviewed journals about many of the clinical trials with cTn.
Although attention was called to these issues 10 years ago (2),
progress has been slow. Our recent report deﬁned some of these
important issues (3).Wewill continue to speak out about these issues,
as illustrated by a recent report that deﬁnes the distorting effects of
using contemporary assays as a gold standard for the timing of
including or excluding acute myocardial infarction and for calcu-
lating change criteria with high-sensitivity cTn assays (4).
Furthermore, establishing a more consistent regulatory approval
processes would improve the confusion in this area. Protocols vary
more than would be ideal and lead to analytical and clinical study
results that are inconsistent and confusing. Finally, we should
consider how assays that fail to meet modern-day standards are
identiﬁed so that their use can be limited or discontinued, because
there is no regulatory process to remove them from the market.
These approaches might have a better chance at providing the
assistance that Drs. Lippi and Cervellin desire than attempting to
dissolve the concept of a competitive marketplace in this isolated
area of medicine.Fred K. Korley, MD
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